Vanda Pharmaceuticals Inc.(VNDA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Vanda Pharmaceuticals Inc. (VNDA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNDA at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,655 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (3.3) and profitability (6.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Vanda Pharmaceuticals Inc. reports quarterly revenue of $50.5M, net income of $-62.5M, free cash flow of $-31.3M. Top institutional holders of VNDA by reported 13-F value include BlackRock, STATE STREET, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. VNDA trades on the Nasdaq exchange and files with the SEC under CIK 1347178. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vanda Pharmaceuticals Inc. directly from SEC EDGAR.